Literature DB >> 7104231

Dosage and control of oral anticoagulants: an international collaborative survey.

L Poller, D A Taberner.   

Abstract

An international survey of oral anticoagulant dosage has been carried out comparing the mean dosage prescribed in hospitals in 23 countries. In addition, participants using the Quick prothrombin time test were asked to assess the adequacy of dosage of a lyophilized test plasma which was mid-therapeutic using the British Comparative Thromboplastin (BCT). The overall mean dosage proved similar for the groups of laboratories using the Quick test and human brain thromboplastin and Thrombotest although wide differences existed between individual centres. The survey indicated that these discrepancies were due partly to the adoption of different intensities of anticoagulation. In addition, local differences in patients' response to anticoagulants were apparent, e.g. North American centres prescribed a higher mean dose with a more intense therapeutic range than Europeans. Hong Kong physicians appear to prescribe a much lower dose than the rest of the world although the intensity of their treatment is comparable, whereas South African hospitals give moderate doses of warfarin despite a conservative therapeutic range. Such geographical variation in response would invalidate standardization of anticoagulant treatment based on the mean dosage approach.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104231     DOI: 10.1111/j.1365-2141.1982.tb02805.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Safety of anticoagulation in the elderly: reasons for discontinuing therapy.

Authors:  P A O'Neill; D Crossley; D A Taberner; D S Fairweather
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

Review 2.  Therapeutic ranges for oral anticoagulation in different thromboembolic disorders.

Authors:  L Poller
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

3.  Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study.

Authors:  L Poller; P K MacCallum; J M Thomson; W Kerns
Journal:  Br Heart J       Date:  1990-04

4.  Monitoring oral anticoagulation in primary care.

Authors:  D A Fitzmaurice; F D Hobbs; J A Murray
Journal:  BMJ       Date:  1996-06-08

5.  Laboratory control of oral anticoagulants.

Authors:  L Poller
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

6.  Therapeutic ranges in anticoagulant administration.

Authors:  L Poller
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-08

Review 7.  Drug treatment associated with heart valve replacement.

Authors:  D S Coulshed; M A Fitzpatrick; C H Lee
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Eunice Yuen; Ivelina Gueorguieva; Stephen Wise; Danny Soon; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-26       Impact factor: 2.745

9.  Factors affecting the maintenance dose of warfarin.

Authors:  A H James; R P Britt; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

10.  Effect of the choice of WHO International Reference Preparation for thromboplastin on International Normalised Ratios.

Authors:  L Poller; D A Taberner; J M Thomson; J Morris; R S Mibashan; N K Shinton
Journal:  J Clin Pathol       Date:  1993-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.